|
US836805A
(en)
|
1904-05-10 |
1906-11-27 |
Alva Battie Dozier |
Telephone or switchboard plug.
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US3992518A
(en)
|
1974-10-24 |
1976-11-16 |
G. D. Searle & Co. |
Method for making a microsealed delivery device
|
|
GB1478759A
(en)
|
1974-11-18 |
1977-07-06 |
Alza Corp |
Process for forming outlet passageways in pills using a laser
|
|
US4284444A
(en)
|
1977-08-01 |
1981-08-18 |
Herculite Protective Fabrics Corporation |
Activated polymer materials and process for making same
|
|
US4704362A
(en)
|
1977-11-08 |
1987-11-03 |
Genentech, Inc. |
Recombinant cloning vehicle microbial polypeptide expression
|
|
US4200098A
(en)
|
1978-10-23 |
1980-04-29 |
Alza Corporation |
Osmotic system with distribution zone for dispensing beneficial agent
|
|
US4235881A
(en)
|
1978-12-04 |
1980-11-25 |
Cort Joseph H |
Method for producing high potency factor VIII
|
|
US4200984A
(en)
|
1979-03-12 |
1980-05-06 |
Fink Ray D |
Detachable tool combining bracket and method
|
|
US4342832A
(en)
|
1979-07-05 |
1982-08-03 |
Genentech, Inc. |
Method of constructing a replicable cloning vehicle having quasi-synthetic genes
|
|
US4215051A
(en)
|
1979-08-29 |
1980-07-29 |
Standard Oil Company (Indiana) |
Formation, purification and recovery of phthalic anhydride
|
|
ZA811368B
(en)
|
1980-03-24 |
1982-04-28 |
Genentech Inc |
Bacterial polypedtide expression employing tryptophan promoter-operator
|
|
US4398908A
(en)
|
1980-11-28 |
1983-08-16 |
Siposs George G |
Insulin delivery system
|
|
US4456591A
(en)
|
1981-06-25 |
1984-06-26 |
Baxter Travenol Laboratories, Inc. |
Therapeutic method for activating factor VII
|
|
US4435173A
(en)
|
1982-03-05 |
1984-03-06 |
Delta Medical Industries |
Variable rate syringe pump for insulin delivery
|
|
US4542025A
(en)
|
1982-07-29 |
1985-09-17 |
The Stolle Research And Development Corporation |
Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
|
|
US4599311A
(en)
|
1982-08-13 |
1986-07-08 |
Kawasaki Glenn H |
Glycolytic promotersfor regulated protein expression: protease inhibitor
|
|
US4713339A
(en)
|
1983-01-19 |
1987-12-15 |
Genentech, Inc. |
Polycistronic expression vector construction
|
|
US4870008A
(en)
|
1983-08-12 |
1989-09-26 |
Chiron Corporation |
Secretory expression in eukaryotes
|
|
US4757006A
(en)
|
1983-10-28 |
1988-07-12 |
Genetics Institute, Inc. |
Human factor VIII:C gene and recombinant methods for production
|
|
US7138505B1
(en)
|
1984-01-12 |
2006-11-21 |
Novartis Vaccines And Diagnostics, Inc. |
Factor VIII:C nucleic acid molecules
|
|
US5004804A
(en)
|
1984-01-12 |
1991-04-02 |
Nordisk Gentofte |
Method and composition for preparation of factor VIIIC
|
|
EP0154316B1
(fr)
|
1984-03-06 |
1989-09-13 |
Takeda Chemical Industries, Ltd. |
Lymphokine chimiquement modifiée et son procédé de préparation
|
|
US5231112A
(en)
|
1984-04-12 |
1993-07-27 |
The Liposome Company, Inc. |
Compositions containing tris salt of cholesterol hemisuccinate and antifungal
|
|
US5916588A
(en)
|
1984-04-12 |
1999-06-29 |
The Liposome Company, Inc. |
Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
|
|
US4965199A
(en)
|
1984-04-20 |
1990-10-23 |
Genentech, Inc. |
Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
|
|
US4931373A
(en)
|
1984-05-25 |
1990-06-05 |
Zymogenetics, Inc. |
Stable DNA constructs for expression of α-1 antitrypsin
|
|
ATE59302T1
(de)
|
1984-07-24 |
1991-01-15 |
Key Pharma |
Klebende schicht zur transdermalen freigabe.
|
|
US4766073A
(en)
|
1985-02-25 |
1988-08-23 |
Zymogenetics Inc. |
Expression of biologically active PDGF analogs in eucaryotic cells
|
|
US4885249A
(en)
|
1984-12-05 |
1989-12-05 |
Allelix, Inc. |
Aspergillus niger transformation system
|
|
US4970300A
(en)
|
1985-02-01 |
1990-11-13 |
New York University |
Modified factor VIII
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4965188A
(en)
|
1986-08-22 |
1990-10-23 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
|
|
US5981216A
(en)
|
1985-04-01 |
1999-11-09 |
Alusuisse Holdings A.G. |
Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
|
|
JPH0788399B2
(ja)
|
1985-04-12 |
1995-09-27 |
ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド |
新規プロコアギュラント蛋白質
|
|
GR860984B
(en)
|
1985-04-17 |
1986-08-18 |
Zymogenetics Inc |
Expression of factor vii and ix activities in mammalian cells
|
|
AU5864086A
(en)
|
1985-04-22 |
1986-11-18 |
Genetics Institute Inc. |
High yield production of active factor ix
|
|
US4684479A
(en)
|
1985-08-14 |
1987-08-04 |
Arrigo Joseph S D |
Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
|
|
KR910006424B1
(ko)
|
1985-08-21 |
1991-08-24 |
인코텍스 비.브이 |
편성브리프(brief) 제조방법
|
|
US4882279A
(en)
|
1985-10-25 |
1989-11-21 |
Phillips Petroleum Company |
Site selective genomic modification of yeast of the genus pichia
|
|
US5198349A
(en)
|
1986-01-03 |
1993-03-30 |
Genetics Institute, Inc. |
Method for producing factor VIII:C and analogs
|
|
US5250421A
(en)
|
1986-01-03 |
1993-10-05 |
Genetics Institute, Inc. |
Method for producing factor VIII:C-type proteins
|
|
WO1987004187A1
(fr)
|
1986-01-03 |
1987-07-16 |
Genetics Institute, Inc. |
PROCEDE DE PRODUCTION DE PROTEINES DE TYPE FACTEUR VIII:c
|
|
US4935349A
(en)
|
1986-01-17 |
1990-06-19 |
Zymogenetics, Inc. |
Expression of higher eucaryotic genes in aspergillus
|
|
US5595886A
(en)
|
1986-01-27 |
1997-01-21 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
|
DK122686D0
(da)
|
1986-03-17 |
1986-03-17 |
Novo Industri As |
Fremstilling af proteiner
|
|
GB8610600D0
(en)
|
1986-04-30 |
1986-06-04 |
Novo Industri As |
Transformation of trichoderma
|
|
US5422260A
(en)
|
1986-05-29 |
1995-06-06 |
Genetics Institute, Inc. -Legal Affairs |
Human factor VIII:c muteins
|
|
US6759057B1
(en)
|
1986-06-12 |
2004-07-06 |
The Liposome Company, Inc. |
Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
|
|
US5543502A
(en)
|
1986-06-24 |
1996-08-06 |
Novo Nordisk A/S |
Process for producing a coagulation active complex of factor VIII fragments
|
|
IE60901B1
(en)
|
1986-08-21 |
1994-08-24 |
Vestar Inc |
Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
|
|
US4933185A
(en)
|
1986-09-24 |
1990-06-12 |
Massachusetts Institute Of Technology |
System for controlled release of biologically active compounds
|
|
US6024983A
(en)
|
1986-10-24 |
2000-02-15 |
Southern Research Institute |
Composition for delivering bioactive agents for immune response and its preparation
|
|
US4912040A
(en)
|
1986-11-14 |
1990-03-27 |
Genetics Institute, Inc. |
Eucaryotic expression system
|
|
US6406713B1
(en)
|
1987-03-05 |
2002-06-18 |
The Liposome Company, Inc. |
Methods of preparing low-toxicity drug-lipid complexes
|
|
US4775207A
(en)
|
1987-03-17 |
1988-10-04 |
Bell Communications Research, Inc. |
Electro-optical switch
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
CA1331157C
(fr)
|
1987-04-06 |
1994-08-02 |
Randal J. Kaufman |
Methode de production du facteur viii : proteines de type c
|
|
US6060447A
(en)
|
1987-05-19 |
2000-05-09 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
|
US5171844A
(en)
|
1987-06-12 |
1992-12-15 |
Gist-Brocades N.W. |
Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
|
US6346513B1
(en)
|
1987-06-12 |
2002-02-12 |
Baxter Trading Gmbh |
Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
|
DE3720246A1
(de)
|
1987-06-19 |
1988-12-29 |
Behringwerke Ag |
Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
|
|
US4897268A
(en)
|
1987-08-03 |
1990-01-30 |
Southern Research Institute |
Drug delivery system and method of making the same
|
|
US4976696A
(en)
|
1987-08-10 |
1990-12-11 |
Becton, Dickinson And Company |
Syringe pump and the like for delivering medication
|
|
FR2619314B1
(fr)
|
1987-08-11 |
1990-06-15 |
Transgene Sa |
Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
|
|
US4861800A
(en)
|
1987-08-18 |
1989-08-29 |
Buyske Donald A |
Method for administering the drug deprenyl so as to minimize the danger of side effects
|
|
US4994371A
(en)
|
1987-08-28 |
1991-02-19 |
Davie Earl W |
DNA preparation of Christmas factor and use of DNA sequences
|
|
AU598958B2
(en)
|
1987-11-12 |
1990-07-05 |
Vestar, Inc. |
Improved amphotericin b liposome preparation
|
|
US5270176A
(en)
|
1987-11-20 |
1993-12-14 |
Hoechst Aktiengesellschaft |
Method for the selective cleavage of fusion proteins with lysostaphin
|
|
GB8807504D0
(en)
|
1988-03-29 |
1988-05-05 |
Sandoz Ltd |
Improvements in/relating to organic compounds
|
|
US5037743A
(en)
|
1988-08-05 |
1991-08-06 |
Zymogenetics, Inc. |
BAR1 secretion signal
|
|
JP2717808B2
(ja)
|
1988-08-10 |
1998-02-25 |
テルモ株式会社 |
シリンジポンプ
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5534617A
(en)
|
1988-10-28 |
1996-07-09 |
Genentech, Inc. |
Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
|
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
|
US5004803A
(en)
|
1988-11-14 |
1991-04-02 |
Genetics Institute, Inc. |
Production of procoagulant proteins
|
|
JP2989002B2
(ja)
|
1988-12-22 |
1999-12-13 |
キリン―アムジエン・インコーポレーテツド |
化学修飾顆粒球コロニー刺激因子
|
|
AU648020B2
(en)
|
1989-02-21 |
1994-04-14 |
Washington University |
Modified forms of reproductive hormones
|
|
US5017378A
(en)
|
1989-05-01 |
1991-05-21 |
The University Of Virginia Alumni Patents Foundation |
Intraorgan injection of biologically active compounds contained in slow-release microcapsules or microspheres
|
|
ES2084698T5
(es)
|
1989-05-04 |
2005-03-01 |
Southern Research Institute |
Procedimiento de encapsulacion.
|
|
US5599907A
(en)
|
1989-05-10 |
1997-02-04 |
Somatogen, Inc. |
Production and use of multimeric hemoglobins
|
|
US5298022A
(en)
|
1989-05-29 |
1994-03-29 |
Amplifon Spa |
Wearable artificial pancreas
|
|
FR2647677B1
(fr)
|
1989-05-31 |
1991-09-27 |
Roussel Uclaf |
Nouvelles micro-proteines, procede de preparation et application a titre de medicaments de ces nouvelles micro-proteines
|
|
US7413537B2
(en)
|
1989-09-01 |
2008-08-19 |
Dyax Corp. |
Directed evolution of disulfide-bonded micro-proteins
|
|
SE465222C5
(sv)
|
1989-12-15 |
1998-02-10 |
Pharmacia & Upjohn Ab |
Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
|
|
US5492534A
(en)
|
1990-04-02 |
1996-02-20 |
Pharmetrix Corporation |
Controlled release portable pump
|
|
US5318540A
(en)
|
1990-04-02 |
1994-06-07 |
Pharmetrix Corporation |
Controlled release infusion device
|
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
|
US5176502A
(en)
|
1990-04-25 |
1993-01-05 |
Becton, Dickinson And Company |
Syringe pump and the like for delivering medication
|
|
US6517859B1
(en)
|
1990-05-16 |
2003-02-11 |
Southern Research Institute |
Microcapsules for administration of neuroactive agents
|
|
US5215680A
(en)
|
1990-07-10 |
1993-06-01 |
Cavitation-Control Technology, Inc. |
Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
|
|
US5583107A
(en)
|
1990-09-04 |
1996-12-10 |
Cor Therapeutics, Inc. |
Agents affecting thrombosis and hemostasis
|
|
CA2094512A1
(fr)
|
1990-12-13 |
1992-06-14 |
Teresa M. Kubiak |
Polypeptides de fusion
|
|
US5206161A
(en)
|
1991-02-01 |
1993-04-27 |
Genentech, Inc. |
Human plasma carboxypeptidase B
|
|
US20060122376A1
(en)
|
1991-02-07 |
2006-06-08 |
Chiron Corporation |
Protein complexes having factor VIII:C activity and production thereof
|
|
US5833982A
(en)
|
1991-02-28 |
1998-11-10 |
Zymogenetics, Inc. |
Modified factor VII
|
|
DE69233069T2
(de)
|
1991-03-15 |
2003-11-27 |
Amgen Inc., Thousand Oaks |
Pegylation von polypeptiden
|
|
US5846951A
(en)
|
1991-06-06 |
1998-12-08 |
The School Of Pharmacy, University Of London |
Pharmaceutical compositions
|
|
MX9204374A
(es)
|
1991-07-25 |
1993-03-01 |
Idec Pharma Corp |
Anticuerpo recombinante y metodo para su produccion.
|
|
CA2078721A1
(fr)
|
1991-09-24 |
1993-03-25 |
Hiroshi Yonemura |
Methode de preparation d'un complexe proteique du facteur viii de coagulation humaine
|
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
|
US6376463B1
(en)
|
1992-04-07 |
2002-04-23 |
Emory University |
Modified factor VIII
|
|
US5364771A
(en)
|
1992-04-07 |
1994-11-15 |
Emory University |
Hybrid human/porcine factor VIII
|
|
US5859204A
(en)
|
1992-04-07 |
1999-01-12 |
Emory University |
Modified factor VIII
|
|
US6037452A
(en)
|
1992-04-10 |
2000-03-14 |
Alpha Therapeutic Corporation |
Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
|
|
CZ290342B6
(cs)
|
1992-10-02 |
2002-07-17 |
Genetics Institute Inc. |
Kompozice stabilní při skladování, obsahující koagulační faktor VIII a neiontovou povrchově aktivní látku a způsob její výroby
|
|
US5563045A
(en)
|
1992-11-13 |
1996-10-08 |
Genetics Institute, Inc. |
Chimeric procoagulant proteins
|
|
DE669986T1
(de)
|
1992-11-13 |
1996-10-10 |
Idec Pharma Corp |
Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung.
|
|
US5573776A
(en)
|
1992-12-02 |
1996-11-12 |
Alza Corporation |
Oral osmotic device with hydrogel driving member
|
|
US5554730A
(en)
|
1993-03-09 |
1996-09-10 |
Middlesex Sciences, Inc. |
Method and kit for making a polysaccharide-protein conjugate
|
|
CA2157793C
(fr)
|
1993-03-09 |
1999-07-13 |
James E. Woiszwillo |
Microparticules macromoleculaires et methode de production
|
|
US6090925A
(en)
|
1993-03-09 |
2000-07-18 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
|
US5981719A
(en)
|
1993-03-09 |
1999-11-09 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
|
SE504074C2
(sv)
|
1993-07-05 |
1996-11-04 |
Pharmacia Ab |
Proteinberedning för subkutan, intramuskulär eller intradermal administrering
|
|
US5576291A
(en)
|
1993-09-13 |
1996-11-19 |
Baxter International Inc. |
Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
|
|
US5643575A
(en)
|
1993-10-27 |
1997-07-01 |
Enzon, Inc. |
Non-antigenic branched polymer conjugates
|
|
US20020042079A1
(en)
|
1994-02-01 |
2002-04-11 |
Sanford M. Simon |
Methods and agents for measuring and controlling multidrug resistance
|
|
US5660848A
(en)
|
1994-11-02 |
1997-08-26 |
The Population Council, Center For Biomedical Research |
Subdermally implantable device
|
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
|
SE503424C2
(sv)
|
1994-11-14 |
1996-06-10 |
Pharmacia Ab |
Process för rening av rekombinant koagulationsfaktor VIII
|
|
US6818439B1
(en)
|
1994-12-30 |
2004-11-16 |
Chiron Corporation |
Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
|
|
US6485726B1
(en)
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
US6086875A
(en)
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
US7846455B2
(en)
|
1996-07-15 |
2010-12-07 |
The United States Of America As Represented By The Department Of Health And Human Services |
Attenuated chimeric respiratory syncytial virus
|
|
SE9503380D0
(sv)
|
1995-09-29 |
1995-09-29 |
Pharmacia Ab |
Protein derivatives
|
|
GB9526733D0
(en)
|
1995-12-30 |
1996-02-28 |
Delta Biotechnology Ltd |
Fusion proteins
|
|
US5977163A
(en)
|
1996-03-12 |
1999-11-02 |
Pg-Txl Company, L. P. |
Water soluble paclitaxel prodrugs
|
|
US6441025B2
(en)
|
1996-03-12 |
2002-08-27 |
Pg-Txl Company, L.P. |
Water soluble paclitaxel derivatives
|
|
US8183344B2
(en)
|
1996-04-24 |
2012-05-22 |
University Of Michigan |
Inactivation resistant factor VIII
|
|
US7560107B2
(en)
|
1996-06-26 |
2009-07-14 |
Emory University |
Modified factor VIII
|
|
US6458563B1
(en)
|
1996-06-26 |
2002-10-01 |
Emory University |
Modified factor VIII
|
|
WO1998005787A1
(fr)
|
1996-08-02 |
1998-02-12 |
Bristol-Myers Squibb Company |
Procede servant a inhiber la toxicite provoquee par les immunoglobulines provenant de l'utilisation d'immunoglobulines en therapie et en diagnostic in vivo
|
|
PT929293E
(pt)
|
1996-08-23 |
2004-03-31 |
Sequus Pharm Inc |
Lipossomas contendo um composto de cisplatina
|
|
JP2001503396A
(ja)
|
1996-10-11 |
2001-03-13 |
アルザ コーポレイション |
治療用リポソーム組成物および方法
|
|
US6056973A
(en)
|
1996-10-11 |
2000-05-02 |
Sequus Pharmaceuticals, Inc. |
Therapeutic liposome composition and method of preparation
|
|
HUP0000522A3
(en)
|
1996-10-15 |
2000-10-30 |
Transave Inc Monmouth Junction |
N-acyl phoshpatidylethanolamine-mediated liposomal drug delivery
|
|
US6361796B1
(en)
|
1996-10-25 |
2002-03-26 |
Shire Laboratories, Inc. |
Soluble form osmotic dose delivery system
|
|
JP4863534B2
(ja)
|
1996-10-25 |
2012-01-25 |
スパーナス ファーマシューティカルズ インコーポレイテッド |
可溶形態浸透用量送達システム
|
|
WO1998022577A1
(fr)
|
1996-11-15 |
1998-05-28 |
Maria Grazia Masucci |
Proteines de fusion a demi-vie allongee
|
|
EP0842657A1
(fr)
|
1996-11-19 |
1998-05-20 |
OctoPlus B.V. |
Microsphères pour la libération contrÔlée et procédés pour la préparation de telles microsphères
|
|
US6395302B1
(en)
|
1996-11-19 |
2002-05-28 |
Octoplus B.V. |
Method for the preparation of microspheres which contain colloidal systems
|
|
WO1998023289A1
(fr)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
Modulation de la fixation de l'igg au fcrn
|
|
US20020019036A1
(en)
|
1996-12-13 |
2002-02-14 |
Hans-Peter Schwarz |
Von willebrand factor derivatives and methods of isolating proteins that bind to von willebrand factor
|
|
US6294170B1
(en)
|
1997-08-08 |
2001-09-25 |
Amgen Inc. |
Composition and method for treating inflammatory diseases
|
|
AT405516B
(de)
|
1997-02-27 |
1999-09-27 |
Immuno Ag |
Faktor x-analoge mit modifizierter proteasespaltstelle
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
CA2225189C
(fr)
|
1997-03-06 |
2010-05-25 |
Queen's University At Kingston |
Gene et proteine du facteur viii du chien et methodes d'utilisation
|
|
PL191251B1
(pl)
|
1997-03-14 |
2006-04-28 |
Idec Pharma Corp |
Sposób wprowadzania żądanego DNA w docelowe miejsce w genomie ssaka i układ wektorów
|
|
DE69833755T2
(de)
|
1997-05-21 |
2006-12-28 |
Biovation Ltd. |
Verfahren zur herstellung von nicht-immunogenen proteinen
|
|
US7786070B2
(en)
|
1997-09-10 |
2010-08-31 |
Novo Nordisk Healthcare A/G |
Subcutaneous administration of coagulation factor VII
|
|
US6310183B1
(en)
|
1997-09-10 |
2001-10-30 |
Novo Nordisk A/S |
Coagulation factor VIIa composition
|
|
DE19747261A1
(de)
|
1997-10-25 |
1999-04-29 |
Bayer Ag |
Osmotisches Arzneimittelfreisetzungssystem
|
|
GB9722131D0
(en)
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
|
EP1563866B1
(fr)
|
1998-02-05 |
2007-10-03 |
Biosense Webster, Inc. |
Appareil pour l'administration de medicament intracardiaque
|
|
US20050260605A1
(en)
|
1998-02-11 |
2005-11-24 |
Maxygen, Inc. |
Targeting of genetic vaccine vectors
|
|
CA2320958A1
(fr)
|
1998-02-11 |
1999-08-19 |
Maxygen, Inc. |
Immunisation par bibliotheque d'antigenes
|
|
DE69937291T2
(de)
|
1998-04-02 |
2008-07-10 |
Genentech, Inc., South San Francisco |
Antikörpervarianten und fragmente davon
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6406632B1
(en)
|
1998-04-03 |
2002-06-18 |
Symyx Technologies, Inc. |
Rapid characterization of polymers
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
US7090976B2
(en)
|
1999-11-10 |
2006-08-15 |
Rigel Pharmaceuticals, Inc. |
Methods and compositions comprising Renilla GFP
|
|
GB9815157D0
(en)
|
1998-07-13 |
1998-09-09 |
Metron Designs Ltd |
High resolution pulse width setting from relatively low frequency clocks
|
|
US20020142374A1
(en)
|
1998-08-17 |
2002-10-03 |
Michael Gallo |
Generation of modified molecules with increased serum half-lives
|
|
US6927044B2
(en)
|
1998-09-25 |
2005-08-09 |
Regeneron Pharmaceuticals, Inc. |
IL-1 receptor based cytokine traps
|
|
EP1129186B2
(fr)
|
1998-11-10 |
2016-11-30 |
Stichting Sanquin Bloedvoorziening |
Polypeptide du facteur viii avec activite de facteur viii:c
|
|
EP1006183A1
(fr)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Récepteurs Fc recombinantes et solubles
|
|
US6329186B1
(en)
|
1998-12-07 |
2001-12-11 |
Novozymes A/S |
Glucoamylases with N-terminal extensions
|
|
US6358703B1
(en)
|
1998-12-10 |
2002-03-19 |
Bayer Corporation |
Expression system for factor VIII
|
|
US6713086B2
(en)
|
1998-12-18 |
2004-03-30 |
Abbott Laboratories |
Controlled release formulation of divalproex sodium
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
KR101077001B1
(ko)
|
1999-01-15 |
2011-10-26 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
US6715485B1
(en)
|
1999-03-03 |
2004-04-06 |
Optinose As |
Nasal delivery device
|
|
US6183770B1
(en)
|
1999-04-15 |
2001-02-06 |
Acutek International |
Carrier patch for the delivery of agents to the skin
|
|
US7666400B2
(en)
|
2005-04-06 |
2010-02-23 |
Ibc Pharmaceuticals, Inc. |
PEGylation by the dock and lock (DNL) technique
|
|
US6743211B1
(en)
|
1999-11-23 |
2004-06-01 |
Georgia Tech Research Corporation |
Devices and methods for enhanced microneedle penetration of biological barriers
|
|
WO2005016455A2
(fr)
|
2003-08-14 |
2005-02-24 |
D. Collen Research Foundation Vzw |
Anticorps variables
|
|
US7829085B2
(en)
|
1999-07-14 |
2010-11-09 |
Life Sciences Research Partners Vzw |
Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
|
|
CA2378473A1
(fr)
|
1999-07-23 |
2001-02-01 |
The Regents Of The University Of California |
Modulation de l'activation plaquettaire
|
|
ATE279437T1
(de)
|
1999-08-06 |
2004-10-15 |
Genentech Inc |
Peptidantagonisten des faktors viia
|
|
US6458387B1
(en)
|
1999-10-18 |
2002-10-01 |
Epic Therapeutics, Inc. |
Sustained release microspheres
|
|
US20030109428A1
(en)
|
1999-12-01 |
2003-06-12 |
John Bertin |
Novel molecules of the card-related protein family and uses thereof
|
|
US20050287153A1
(en)
|
2002-06-28 |
2005-12-29 |
Genentech, Inc. |
Serum albumin binding peptides for tumor targeting
|
|
US6352721B1
(en)
|
2000-01-14 |
2002-03-05 |
Osmotica Corp. |
Combined diffusion/osmotic pumping drug delivery system
|
|
DK1252192T3
(da)
|
2000-02-11 |
2006-11-20 |
Merck Patent Gmbh |
Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
|
|
PL204285B1
(pl)
|
2000-02-11 |
2009-12-31 |
Bayer Healthcare Llc |
Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
|
|
JP2003530838A
(ja)
|
2000-04-12 |
2003-10-21 |
ヒューマン ゲノム サイエンシズ インコーポレイテッド |
アルブミン融合タンパク質
|
|
JP2003533537A
(ja)
|
2000-05-16 |
2003-11-11 |
リポクセン テクノロジーズ リミテッド |
タンパク質の誘導体化
|
|
JP2001326635A
(ja)
|
2000-05-16 |
2001-11-22 |
Matsushita Electric Ind Co Ltd |
インターネットの課金システム
|
|
KR100867392B1
(ko)
|
2000-08-15 |
2008-11-06 |
더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 |
마이크로입자
|
|
CZ2003611A3
(cs)
|
2000-09-13 |
2003-08-13 |
Novo Nordisk A/S |
Varianty lidského koagulačního faktoru VII
|
|
MXPA03002256A
(es)
|
2000-09-19 |
2003-09-10 |
Univ Emory |
Factor viii modificado.
|
|
DE10053224A1
(de)
|
2000-10-26 |
2002-05-08 |
Univ Goettingen Georg August |
Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
|
|
US20030228309A1
(en)
|
2000-11-08 |
2003-12-11 |
Theodora Salcedo |
Antibodies that immunospecifically bind to TRAIL receptors
|
|
AU2002226028A1
(en)
|
2000-11-14 |
2002-05-27 |
Board Of Regents, Unversity Of Texas Systems |
Mutant human factor ix with an increased resistance to inhibition by heparin
|
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
US20030104591A1
(en)
|
2000-12-14 |
2003-06-05 |
Murray Christopher J. |
Methods and compositions for grafting functional loops into a protein
|
|
US20030049689A1
(en)
|
2000-12-14 |
2003-03-13 |
Cynthia Edwards |
Multifunctional polypeptides
|
|
EP1354042A2
(fr)
|
2000-12-29 |
2003-10-22 |
Curagen Corporation |
Proteines et acides nucleiques codant celles-ci
|
|
IN190699B
(fr)
|
2001-02-02 |
2003-08-16 |
Sun Pharmaceutical Ind Ltd |
|
|
CA2436807A1
(fr)
|
2001-02-05 |
2002-08-15 |
Novo Nordisk Health Care Ag |
Utilisation combinee de polypeptides de facteur vii et des polypeptides de facteur viii
|
|
US6888319B2
(en)
|
2001-03-01 |
2005-05-03 |
Palomar Medical Technologies, Inc. |
Flashlamp drive circuit
|
|
CA2440582A1
(fr)
|
2001-03-09 |
2002-10-03 |
Dyax Corp. |
Groupes de liaison d'albumine serique
|
|
US20020169125A1
(en)
|
2001-03-21 |
2002-11-14 |
Cell Therapeutics, Inc. |
Recombinant production of polyanionic polymers and uses thereof
|
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
|
US20040106794A1
(en)
|
2001-04-16 |
2004-06-03 |
Schering Corporation |
3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
|
|
US20050048512A1
(en)
|
2001-04-26 |
2005-03-03 |
Avidia Research Institute |
Combinatorial libraries of monomer domains
|
|
WO2002087621A1
(fr)
|
2001-04-30 |
2002-11-07 |
Shire Laboratories Inc. |
Preparation pharmaceutique comprenant des inhibiteurs de l'ace/nep et des renforcateurs de biodisponibilite
|
|
TW503179B
(en)
|
2001-05-07 |
2002-09-21 |
Benq Corp |
Ink jetting device having bubble valve and the method thereof
|
|
US6838093B2
(en)
|
2001-06-01 |
2005-01-04 |
Shire Laboratories, Inc. |
System for osmotic delivery of pharmaceutically active agents
|
|
NZ530131A
(en)
|
2001-06-15 |
2005-12-23 |
Andre C |
Gene therapy for hemophilia A
|
|
KR100407467B1
(ko)
|
2001-07-12 |
2003-11-28 |
최수봉 |
리모컨 방식의 인슐린 자동주사기
|
|
US20040259780A1
(en)
|
2001-07-30 |
2004-12-23 |
Glasebrook Andrew Lawrence |
Method for treating diabetes and obesity
|
|
MXPA04001982A
(es)
|
2001-09-04 |
2004-06-07 |
Merck Patent Gmbh |
Factor ix modificado.
|
|
JP2003110596A
(ja)
|
2001-09-28 |
2003-04-11 |
Hitachi Ltd |
データ通信サービス提供方法
|
|
US7125843B2
(en)
|
2001-10-19 |
2006-10-24 |
Neose Technologies, Inc. |
Glycoconjugates including more than one peptide
|
|
EP2305312B1
(fr)
|
2001-10-10 |
2015-03-04 |
ratiopharm GmbH |
Remodelage et glycoconjugation de l'hormone folliculo-stimulante (FSH)
|
|
US6960657B2
(en)
|
2001-11-02 |
2005-11-01 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII polypeptides
|
|
CA2469477A1
(fr)
|
2001-12-07 |
2003-06-12 |
Toolgen, Inc. |
Balayage phenotypique de proteines chimeriques
|
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
|
US20080167238A1
(en)
|
2001-12-21 |
2008-07-10 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
|
ES2425738T3
(es)
|
2001-12-21 |
2013-10-17 |
Human Genome Sciences, Inc. |
Proteínas de fusión de la albúmina
|
|
KR101271635B1
(ko)
|
2001-12-21 |
2013-06-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
알부민 융합 단백질
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
CA2478011C
(fr)
|
2002-03-01 |
2013-05-21 |
Immunomedics, Inc. |
Mutations ponctuelles dans un anticorps bispecifique, permettant d'augmenter le taux de clairance
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
AU2002316574B2
(en)
|
2002-03-15 |
2008-05-01 |
Brandeis University |
Central airway administration for systemic delivery of therapeutics
|
|
BR0309576A
(pt)
|
2002-04-30 |
2005-02-09 |
Maxygen Holdings Ltd |
Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável
|
|
US6945952B2
(en)
|
2002-06-25 |
2005-09-20 |
Theraject, Inc. |
Solid solution perforator for drug delivery and other applications
|
|
US7294513B2
(en)
|
2002-07-24 |
2007-11-13 |
Wyatt Technology Corporation |
Method and apparatus for characterizing solutions of small particles
|
|
US7314709B2
(en)
|
2002-08-06 |
2008-01-01 |
Vanderbilt University |
Compositions and methods for detecting and quantifying COX-2 activity by lipoamino acid metabolism
|
|
US7425620B2
(en)
|
2002-08-14 |
2008-09-16 |
Scott Koenig |
FcγRIIB-specific antibodies and methods of use thereof
|
|
AU2003275103A1
(en)
|
2002-09-17 |
2004-04-08 |
Diffusion Science, Inc. |
Electrochemical generation, storage and reaction of hydrogen and oxygen using gas permeable catalyst-coated hollow microspheres
|
|
US6911323B2
(en)
|
2002-09-25 |
2005-06-28 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII polypeptides
|
|
WO2004029207A2
(fr)
|
2002-09-27 |
2004-04-08 |
Xencor Inc. |
Variants fc optimises et methodes destinees a leur generation
|
|
DK1562972T3
(da)
|
2002-10-15 |
2010-12-06 |
Facet Biotech Corp |
Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
|
|
GB2395337B
(en)
|
2002-11-14 |
2005-12-28 |
Gary Michael Wilson |
Warning Unit
|
|
EP2368578A1
(fr)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identification et ingénierie d'anticorps avec régions FC de variante et procédés d'utilisation associés
|
|
US7041635B2
(en)
|
2003-01-28 |
2006-05-09 |
In2Gen Co., Ltd. |
Factor VIII polypeptide
|
|
EP1444986A1
(fr)
|
2003-02-07 |
2004-08-11 |
Aventis Behring GmbH |
Preparation pharmaceutique pour l'amélioration du traitement des maladies liées à une coagulation sanguine diminuée
|
|
CA2788505C
(fr)
|
2003-02-26 |
2018-09-04 |
Nektar Therapeutics |
Conjugues de groupe fonctionnel a facteur polymerique viii
|
|
CA2515798A1
(fr)
|
2003-02-27 |
2004-09-10 |
Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Research Council Of Canada |
Inhibiteurs peptidiques de thrombine en tant qu'anticoagulants puissants
|
|
KR100851263B1
(ko)
|
2003-02-28 |
2008-08-08 |
가부시키가이샤 구라레 |
경화성 수지 조성물
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
US20050176108A1
(en)
|
2003-03-13 |
2005-08-11 |
Young-Min Kim |
Physiologically active polypeptide conjugate having prolonged in vivo half-life
|
|
US7132398B2
(en)
|
2003-05-06 |
2006-11-07 |
Dendreon Corporation |
Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
|
|
US7348004B2
(en)
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
PT1624891E
(pt)
|
2003-05-06 |
2010-01-05 |
Syntonix Pharmaceuticals Inc |
Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
US20070161087A1
(en)
|
2003-05-29 |
2007-07-12 |
Wolfgang Glaesner |
Glp-1 fusion proteins
|
|
JP4644663B2
(ja)
|
2003-06-03 |
2011-03-02 |
セル ジェネシス インコーポレイテッド |
ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法
|
|
AU2004255553B2
(en)
|
2003-06-19 |
2009-08-20 |
Genentech, Inc. |
Compositions and methods for treating coagulation related disorders
|
|
KR101113726B1
(ko)
|
2003-08-12 |
2012-02-27 |
리폭센 테크놀로지즈 리미티드 |
단백질 유도 및 컨쥬게이션용 시알산 유도체
|
|
WO2005024044A2
(fr)
|
2003-09-05 |
2005-03-17 |
Gtc Biotherapeutics, Inc. |
Procede de production de proteines de fusion dans le lait de mammiferes transgeniques
|
|
US20050152979A1
(en)
|
2003-09-05 |
2005-07-14 |
Cell Therapeutics, Inc. |
Hydrophobic drug compositions containing reconstitution enhancer
|
|
ATE547519T1
(de)
|
2003-09-09 |
2012-03-15 |
Novo Nordisk Healthcare Ag |
Gerinnungsfaktor-vii-polypeptide
|
|
CA2539253A1
(fr)
|
2003-09-19 |
2005-03-31 |
Novo Nordisk A/S |
Nouveaux derives de glp-1
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
EP1682106A4
(fr)
|
2003-10-30 |
2008-06-11 |
Univ Emory |
Facteur fviii modifie presentant une immunogenicite reduite par mutagenese d'epitopes a2 et c2
|
|
US7211559B2
(en)
|
2003-10-31 |
2007-05-01 |
University Of Maryland, Baltimore |
Factor VIII compositions and methods
|
|
CA2545603A1
(fr)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
|
|
CA2546580A1
(fr)
|
2003-11-18 |
2005-06-09 |
Iconic Therapeutics, Inc. |
Preparations homogenes de proteines chimeres
|
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
|
WO2005077981A2
(fr)
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Polypeptides fc a nouveaux sites de liaison de ligands fc
|
|
EP1706424B1
(fr)
|
2004-01-12 |
2009-07-22 |
Applied Molecular Evolution, Inc. |
Variants de la region fc
|
|
NZ548513A
(en)
|
2004-01-14 |
2010-05-28 |
Univ Ohio |
Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
|
|
EP1729795B1
(fr)
|
2004-02-09 |
2016-02-03 |
Human Genome Sciences, Inc. |
Proteines hybrides d'albumine
|
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
|
US7276585B2
(en)
|
2004-03-24 |
2007-10-02 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
|
WO2005123780A2
(fr)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Modification des affinites de liaison pour le fcrn ou de la demi-vie serique d'anticorps par mutagenese
|
|
KR100624013B1
(ko)
|
2004-06-25 |
2006-09-19 |
주식회사 녹십자홀딩스 |
동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
|
|
US20080233100A1
(en)
|
2004-06-30 |
2008-09-25 |
Yiyou Chen |
Targeted enzymes
|
|
WO2006085967A2
(fr)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
Anticorps monoclonaux optimises anti-cd20 a variants fc
|
|
CN103172731A
(zh)
|
2004-07-15 |
2013-06-26 |
赞科股份有限公司 |
优化的Fc变体
|
|
ATE400647T1
(de)
|
2004-08-13 |
2008-07-15 |
Hoffmann La Roche |
C-terminale modifikation von polypeptiden
|
|
US7566701B2
(en)
|
2004-09-07 |
2009-07-28 |
Archemix Corp. |
Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
|
|
CN101103045B
(zh)
|
2004-09-24 |
2015-11-25 |
安姆根有限公司 |
修饰的Fc分子
|
|
WO2006047350A2
(fr)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
Variants d'immunoglobuline igg a fonction effectrice optimisee
|
|
US7632921B2
(en)
|
2004-11-12 |
2009-12-15 |
Bayer Healthcare Llc |
Site-directed modification of FVIII
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
CA2587463A1
(fr)
|
2004-11-16 |
2006-11-30 |
Avidia Research Institute |
Squelettes proteiques et leurs utilisations
|
|
DK1835938T3
(da)
|
2004-12-27 |
2013-11-04 |
Baxter Int |
Polymer-von Willebrand-faktor-konjugater
|
|
CN103172747A
(zh)
|
2005-01-25 |
2013-06-26 |
细胞治疗学公司 |
体内半衰期改变的生物活性蛋白质偶联物
|
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
|
WO2006103298A2
(fr)
|
2005-04-01 |
2006-10-05 |
Novo Nordisk Health Care Ag |
Analogues du fviii de coagulation sanguine
|
|
GB0516091D0
(en)
|
2005-08-04 |
2005-09-14 |
Haemostatix Ltd |
Therapeutic agent
|
|
AU2006280312A1
(en)
|
2005-08-12 |
2007-02-22 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
EP1929005A1
(fr)
|
2005-09-21 |
2008-06-11 |
Novo Nordisk Health Care AG |
Polypeptides du facteur vii humain de la coagulation
|
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
JP2009509535A
(ja)
|
2005-09-27 |
2009-03-12 |
アムニクス， インコーポレイテッド |
タンパク様薬剤およびその使用
|
|
US7846445B2
(en)
|
2005-09-27 |
2010-12-07 |
Amunix Operating, Inc. |
Methods for production of unstructured recombinant polymers and uses thereof
|
|
US20090099031A1
(en)
|
2005-09-27 |
2009-04-16 |
Stemmer Willem P |
Genetic package and uses thereof
|
|
US8334257B2
(en)
|
2005-12-20 |
2012-12-18 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
|
US8048848B2
(en)
|
2006-02-03 |
2011-11-01 |
Prolor Biotech Ltd. |
Long-acting interferons and derivatives thereof and methods thereof
|
|
EP1816201A1
(fr)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée
|
|
FR2897868B1
(fr)
|
2006-02-24 |
2012-08-31 |
Lab Francais Du Fractionnement |
Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
|
|
EP2863222A1
(fr)
|
2006-03-06 |
2015-04-22 |
Amunix Operating Inc. |
Polymères recombinants non structurés et leurs utilisations
|
|
CN101406105B
(zh)
|
2006-03-13 |
2010-11-10 |
皇家飞利浦电子股份有限公司 |
用于固态照明系统的自适应控制装置和方法
|
|
US7645860B2
(en)
|
2006-03-31 |
2010-01-12 |
Baxter Healthcare S.A. |
Factor VIII polymer conjugates
|
|
EP2010222A1
(fr)
|
2006-03-31 |
2009-01-07 |
Baxter International Inc. |
Facteur viii pégylé
|
|
JO3324B1
(ar)
|
2006-04-21 |
2019-03-13 |
Amgen Inc |
مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
|
|
US20090169553A1
(en)
|
2006-05-04 |
2009-07-02 |
Molecular Innovations |
Novel Protein Fusion/Tag Technology
|
|
PL2032607T5
(pl)
|
2006-06-14 |
2017-10-31 |
Csl Behring Gmbh |
Rozszczepialne proteolitycznie białko fuzyjne obejmujące czynnik krzepnięcia krwi
|
|
EP1867660A1
(fr)
|
2006-06-14 |
2007-12-19 |
CSL Behring GmbH |
Protéine de fusion qui peut être clivée protéolyticalement et qui contient un facteur de la coagulation sanguine
|
|
US7939632B2
(en)
|
2006-06-14 |
2011-05-10 |
Csl Behring Gmbh |
Proteolytically cleavable fusion proteins with high molar specific activity
|
|
US8383388B2
(en)
|
2006-06-19 |
2013-02-26 |
Catalyst Biosciences, Inc. |
Modified coagulation factor IX polypeptides and use thereof for treatment
|
|
US9187532B2
(en)
|
2006-07-21 |
2015-11-17 |
Novo Nordisk A/S |
Glycosylation of peptides via O-linked glycosylation sequences
|
|
JP5290177B2
(ja)
|
2006-08-31 |
2013-09-18 |
セントカー・インコーポレーテツド |
Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途
|
|
AU2007294805A1
(en)
|
2006-09-14 |
2008-03-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US20100075375A1
(en)
|
2006-10-03 |
2010-03-25 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates
|
|
CA2665480C
(fr)
|
2006-10-04 |
2019-11-12 |
Novo Nordisk A/S |
Glycopeptides et sucres pegyles a liaison glycerol
|
|
WO2008049711A1
(fr)
|
2006-10-27 |
2008-05-02 |
Novo Nordisk A/S |
Insuline à peptide ajouté
|
|
CN101190945A
(zh)
|
2006-11-29 |
2008-06-04 |
中国人民解放军军事医学科学院放射与辐射医学研究所 |
特异性抗凝血物质的制备及其应用
|
|
US8754194B2
(en)
|
2006-12-22 |
2014-06-17 |
Csl Behring Gmbh |
Modified coagulation factors with prolonged in vivo half-life
|
|
EP1935430A1
(fr)
|
2006-12-22 |
2008-06-25 |
CSL Behring GmbH |
Facteurs de coagulation modifiés avec une demi-vie in vivo prolongée
|
|
US8133865B2
(en)
|
2006-12-27 |
2012-03-13 |
Nektar Therapeutics |
von Willebrand factor- and factor VIII-polymer conjugates having a releasable linkage
|
|
WO2008081024A1
(fr)
|
2007-01-03 |
2008-07-10 |
Novo Nordisk Health Care Ag |
Administration sous-cutanée de polypeptides liés au facteur viia de la coagulation
|
|
US7700734B2
(en)
|
2007-01-09 |
2010-04-20 |
Shu-Wha Lin |
Recombinant human factor IX and use thereof
|
|
CA2674879A1
(fr)
|
2007-02-01 |
2008-08-07 |
Baxter International Inc. |
Proteines mutantes de fix ameliorees destinees a traiter l'hemophilie b
|
|
WO2008127702A2
(fr)
|
2007-04-13 |
2008-10-23 |
Catalyst Biosciences, Inc. |
Polypeptides du facteur vii modifiés et leurs utilisations
|
|
AU2008245524A1
(en)
|
2007-04-26 |
2008-11-06 |
Cnj Holdings, Inc. |
Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
|
|
CN101778937A
(zh)
|
2007-06-04 |
2010-07-14 |
诺和诺德公司 |
使用n-乙酰葡糖胺转移酶的o-联糖基化
|
|
EP2486936A1
(fr)
|
2007-06-13 |
2012-08-15 |
CSL Behring GmbH |
Une composition comprenant la préparation du VWF et de FVIII pour utilisation dans le traitement des troubles de la coagulation
|
|
HRP20110368T1
(hr)
|
2007-06-21 |
2011-06-30 |
Technische Universitt Mnchen |
Biološki aktivni proteini s povećanom stabilnošću in vivo i/ili in vitro
|
|
CN103298935A
(zh)
|
2007-08-15 |
2013-09-11 |
阿穆尼克斯公司 |
用于改善生物活性多肽性能的组合物和方法
|
|
AU2008311973B2
(en)
|
2007-10-15 |
2013-10-03 |
Cangene Corporation |
Human Factor IX variants with an extended half life
|
|
EP2209908B1
(fr)
|
2007-11-01 |
2014-09-03 |
University Of Rochester |
Facteur viii recombinant ayant une stabilité accrue
|
|
AU2008323768A1
(en)
|
2007-11-09 |
2009-05-14 |
Baxter Healthcare S.A. |
Modified recombinant Factor VIII and von Willebrand Factor and methods of use
|
|
TW201731488A
(zh)
|
2007-12-28 |
2017-09-16 |
巴克斯歐塔公司 |
重組ｖｗｆ調配物
|
|
KR100981092B1
(ko)
|
2008-02-29 |
2010-09-08 |
고려대학교 산학협력단 |
제8 혈액응고 인자와 폰 빌리 블란트 인자 변이체의 재조합발현 벡터 시스템
|
|
JP5444629B2
(ja)
|
2008-04-03 |
2014-03-19 |
富士通株式会社 |
照度センサ用光案内機構及び携帯電話機
|
|
WO2009140015A2
(fr)
|
2008-04-16 |
2009-11-19 |
Bayer Healthcare Llc |
Modification de facteur ix orientée site
|
|
RU2010146387A
(ru)
|
2008-04-16 |
2012-05-27 |
БАЙЕР ХЕЛСКЕР ЛЛСи (US) |
Модифицированные полипептиды фактора ix и их применение
|
|
TWI541020B
(zh)
|
2008-04-17 |
2016-07-11 |
巴克斯歐塔公司 |
生物活性胜肽
|
|
EP2811017A2
(fr)
|
2008-04-21 |
2014-12-10 |
Novo Nordisk Health Care AG |
Facteur IX de coagulation humain hyperglycosylé
|
|
CN102083469A
(zh)
|
2008-05-06 |
2011-06-01 |
奥克塔法马股份有限公司 |
含有肝素结合蛋白和肝素-羟烷基淀粉缀合物的复合物
|
|
BRPI0913374A2
(pt)
|
2008-06-04 |
2015-11-24 |
Bayer Healthcare Llc |
muteínas fviii para tratamento de doença de von willebrand
|
|
DK2865760T3
(en)
|
2008-06-24 |
2018-01-15 |
Csl Behring Gmbh |
Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
|
|
US20110112022A1
(en)
|
2008-06-25 |
2011-05-12 |
Bayer Healthcare Llc |
Factor VIII Muteins with Reduced Immonugenicity
|
|
ES2571879T3
(es)
|
2008-07-21 |
2016-05-27 |
Apogenix Ag |
Moléculas de una sola cadena de TNFSF
|
|
KR20110093775A
(ko)
|
2008-11-03 |
2011-08-18 |
바이엘 헬스케어 엘엘씨 |
혈우병 치료 방법
|
|
JP2012510060A
(ja)
|
2008-11-24 |
2012-04-26 |
バイエル・ヘルスケア・エルエルシー |
シリカをベースとする活性化部分トロンボプラスチン時間アッセイにおけるｐｅｇ化血液凝固因子の活性の測定方法
|
|
US8703717B2
(en)
|
2009-02-03 |
2014-04-22 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
|
US8680050B2
(en)
|
2009-02-03 |
2014-03-25 |
Amunix Operating Inc. |
Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
|
|
SI2393828T1
(sl)
|
2009-02-03 |
2017-01-31 |
Amunix Operating Inc. |
Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
|
|
US20110046060A1
(en)
|
2009-08-24 |
2011-02-24 |
Amunix Operating, Inc., |
Coagulation factor IX compositions and methods of making and using same
|
|
CL2011001856A1
(es)
|
2009-02-03 |
2012-03-09 |
Amunix Operating Inc |
Polipeptido recombinante extendido aislado (xten) que mejora las propiedades de una proteina biologicamente activa fusionada a el; proteina de fusion aislada que comprende xten ligado a una proteina biologicamente activa; composicion que comprende dicha proteina de fusion; y uso para preparar medicamentos para tratar enfermedades.
|
|
JP5739865B2
(ja)
|
2009-03-24 |
2015-06-24 |
バイエル・ヘルスケア・エルエルシー |
第ｖｉｉｉ因子変異体および使用の方法
|
|
WO2010118435A2
(fr)
|
2009-04-10 |
2010-10-14 |
Tufts Medical Center, Inc. |
Activation de par-1 par la métalloprotéinase-1 (mmp-1)
|
|
GB0908515D0
(en)
|
2009-05-18 |
2009-06-24 |
Apitope Technology Bristol Ltd |
Peptide
|
|
AU2010258898B8
(en)
|
2009-06-08 |
2015-02-05 |
Amunix Operating Inc. |
Glucose-regulating polypeptides and methods of making and using same
|
|
JP5805634B2
(ja)
|
2009-06-08 |
2015-11-04 |
アムニクス オペレーティング インコーポレイテッド |
成長ホルモンポリペプチド並びにその作成及び使用方法
|
|
AU2010284977A1
(en)
|
2009-08-20 |
2012-03-29 |
Csl Behring Gmbh |
Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
|
|
WO2011028344A2
(fr)
|
2009-08-25 |
2011-03-10 |
Amunix Operating Inc. |
Compositions d'antagonistes des récepteurs d'interleukine-1 et leurs procédés de préparation et d'utilisation
|
|
JP5544219B2
(ja)
|
2009-09-24 |
2014-07-09 |
富士フイルム株式会社 |
内視鏡システム
|
|
DK2482841T4
(da)
|
2009-10-02 |
2022-10-24 |
Childrens Hospital Philadelphia |
Sammensætninger og fremgangsmåder til at forbedre koagulationsfaktor-viii-funktion
|
|
TWI423962B
(zh)
|
2009-10-07 |
2014-01-21 |
Lg Life Sciences Ltd |
有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
|
|
HUE029454T2
(en)
|
2009-11-13 |
2017-03-28 |
Grifols Therapeutics Inc |
Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
|
|
WO2011062614A1
(fr)
|
2009-11-20 |
2011-05-26 |
Tonix Pharmaceuticals, Inc. |
Méthodes et compositions destinées à traiter les symptômes associés au stress consécutif à un traumatisme au moyen de cyclobenzaprine
|
|
BR112012013502A2
(pt)
|
2009-12-06 |
2017-01-10 |
Biogen Idec Hemophilia Inc |
"polipeptídeos quiméricos e híbridos de fator viii-fc, e métodos de uso dos mesmos".
|
|
US20110312881A1
(en)
|
2009-12-21 |
2011-12-22 |
Amunix, Inc. |
Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
|
|
EP2536754A1
(fr)
|
2010-02-16 |
2012-12-26 |
Novo Nordisk A/S |
Protéine de fusion du facteur viii
|
|
WO2011101242A1
(fr)
|
2010-02-16 |
2011-08-25 |
Novo Nordisk A/S |
Molécules de facteur viii avec liaison réduite au vwf
|
|
US8466059B2
(en)
|
2010-03-30 |
2013-06-18 |
Taiwan Semiconductor Manufacturing Company, Ltd. |
Multi-layer interconnect structure for stacked dies
|
|
WO2011123830A2
(fr)
|
2010-04-02 |
2011-10-06 |
Amunix Operating Inc. |
Compositions d'alpha 1-antitrypsine, leurs procédés de préparation et d'utilisation
|
|
EP3372617B1
(fr)
|
2010-04-02 |
2024-07-24 |
Amunix Pharmaceuticals, Inc. |
Protéines de fusion liantes, conjugués protéines de fusion liantes-médicaments, conjugués xten-médicaments et procédés pour les préparer et les utiliser
|
|
TWI619713B
(zh)
|
2010-04-21 |
2018-04-01 |
普雷辛肯公司 |
用於激酶調節的化合物和方法及其適應症
|
|
CA3050896C
(fr)
|
2010-04-21 |
2023-01-24 |
Erik Berntorp |
Facteurs genetiques associes a un developpement d'inhibiteurs dans l'hemophilie a
|
|
JP6148979B2
(ja)
|
2010-05-20 |
2017-06-14 |
アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ |
分解性クロストリジウム毒素
|
|
SG10201913700SA
(en)
|
2010-07-09 |
2020-03-30 |
Bioverativ Therapeutics Inc |
Factor ix polypeptides and methods of use thereof
|
|
US9611310B2
(en)
|
2010-07-09 |
2017-04-04 |
Bioverativ Therapeutics Inc. |
Systems for factor VIII processing and methods thereof
|
|
ES2739503T3
(es)
|
2010-07-09 |
2020-01-31 |
Bioverativ Therapeutics Inc |
Moléculas de cadena simple procesables y polipéptidos producidos usándolas
|
|
US20130183280A1
(en)
|
2010-07-15 |
2013-07-18 |
Novo Nordisk A/S |
Stabilized factor viii variants
|
|
US20130017997A1
(en)
|
2010-08-19 |
2013-01-17 |
Amunix Operating Inc. |
Factor VIII Compositions and Methods of Making and Using Same
|
|
ES2724778T3
(es)
|
2011-06-10 |
2019-09-16 |
Bioverativ Therapeutics Inc |
Compuestos procoagulantes y procedimientos de uso de los mismos
|
|
DK2729161T3
(en)
|
2011-07-08 |
2019-04-08 |
Bioverativ Therapeutics Inc |
FACTOR VIII CHEMICAL AND HYBRID POLYPEPTIDES AND PROCEDURES FOR USE THEREOF
|
|
AU2012318292B2
(en)
|
2011-10-18 |
2015-08-20 |
Csl Limited |
Method for improving the stability of purified Factor VIII after reconstitution
|
|
SG10201604962VA
(en)
|
2011-12-21 |
2016-08-30 |
Advanced Tech Materials |
Liner-Based Shipping And Dispensing Systems
|
|
WO2013106786A2
(fr)
|
2012-01-11 |
2013-07-18 |
Boretto Tod Douglas |
Carreau d'arbalète de petit diamètre
|
|
CN111499761A
(zh)
|
2012-01-12 |
2020-08-07 |
比奥贝拉蒂治疗公司 |
嵌合因子viii多肽及其用途
|
|
BR112014017111A8
(pt)
|
2012-01-12 |
2018-05-15 |
Biogen Idec Inc |
métodos de redução de imunogenicidade contra o fator viii em indivíduos submetidos à terapia de fator viii
|
|
NZ628014A
(en)
|
2012-02-15 |
2016-09-30 |
Biogen Ma Inc |
Recombinant factor viii proteins
|
|
CN111548418A
(zh)
|
2012-02-15 |
2020-08-18 |
比奥贝拉蒂治疗公司 |
因子viii组合物及其制备和使用方法
|
|
PL2814502T3
(pl)
|
2012-02-15 |
2018-02-28 |
Csl Behring Gmbh |
Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII
|
|
JP2015519313A
(ja)
|
2012-04-24 |
2015-07-09 |
ノヴォ ノルディスク アー／エス |
血友病の治療に適する医薬組成物
|
|
US20150080309A1
(en)
|
2012-04-24 |
2015-03-19 |
Nova Nordisk A/S |
Compounds Suitable for Treatment of Haemophilia
|
|
WO2013189827A2
(fr)
|
2012-06-22 |
2013-12-27 |
Asml Netherlands B.V. |
Source de rayonnement et appareil lithographique
|
|
AU2013290173B2
(en)
|
2012-07-11 |
2018-02-15 |
Bioverativ Therapeutics Inc. |
Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
|
|
CN104619677B
(zh)
|
2012-07-18 |
2016-10-26 |
西北大学 |
形成乙烯的方法
|
|
EP2914293A4
(fr)
|
2012-10-30 |
2016-04-20 |
Biogen Ma Inc |
Procédés d'utilisation du polypeptide fviii
|
|
WO2014100913A1
(fr)
|
2012-12-24 |
2014-07-03 |
Beijing Anxinhuaide Biotech. Co., Ltd |
Amélioration de la demi-vie d'un polypeptide thérapeutique par fusion avec une protéine d'échafaudage trimère via un espaceur
|
|
EA037906B1
(ru)
|
2013-03-15 |
2021-06-04 |
Биовератив Терапьютикс Инк. |
Препараты полипептида фактора ix
|
|
EP3666283B1
(fr)
|
2013-03-15 |
2022-06-08 |
Bioverativ Therapeutics Inc. |
Formulations de polypeptide de facteur viii
|
|
ES2657291T3
(es)
|
2013-04-22 |
2018-03-02 |
Csl Ltd. |
Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
|
|
TW201536811A
(zh)
|
2013-05-31 |
2015-10-01 |
Biogen Idec Inc |
嵌合ｆｖｉｉ－ｘｔｅｎ分子及其用途
|
|
CN105452289A
(zh)
|
2013-06-12 |
2016-03-30 |
诺和诺德股份有限公司 |
适用于治疗血友病的化合物
|
|
US10272137B2
(en)
|
2013-06-27 |
2019-04-30 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods relating to myomaker-induced muscle cell fusion
|
|
HK1223302A1
(zh)
|
2013-06-28 |
2017-07-28 |
Bioverativ Therapeutics Inc. |
具有xten的凝血酶可裂解连接子和其用途
|
|
EP3013359A4
(fr)
|
2013-06-28 |
2017-01-25 |
Biogen MA Inc. |
Lieur clivable par la thrombine
|
|
EP3043813B1
(fr)
*
|
2013-08-08 |
2021-01-13 |
Bioverativ Therapeutics Inc. |
Purification de molécules chimères du facteur viii
|
|
US10548953B2
(en)
|
2013-08-14 |
2020-02-04 |
Bioverativ Therapeutics Inc. |
Factor VIII-XTEN fusions and uses thereof
|
|
US10325687B2
(en)
|
2013-12-06 |
2019-06-18 |
Bioverativ Therapeutics Inc. |
Population pharmacokinetics tools and uses thereof
|
|
PH12016501323B1
(en)
*
|
2014-01-10 |
2022-04-29 |
Bioverativ Therapeutics Inc |
Factor viii chimeric proteins and uses thereof
|
|
KR20170010895A
(ko)
|
2014-06-06 |
2017-02-01 |
옥타파마 아게 |
인자 ⅷ 및 폰 빌레브란트 인자 펩티드를 포함하는 조제
|
|
EP3164150B1
(fr)
|
2014-07-02 |
2020-11-04 |
CSL Behring Lengnau AG |
Facteur de von willebrand modifié
|
|
EP3193911B1
(fr)
|
2014-07-25 |
2023-09-06 |
CSL Behring GmbH |
Préparations de facteur viii améliorées pour l'utilisation dans le traitement de l'hémophilie a
|
|
AU2015301598B2
(en)
|
2014-08-13 |
2020-07-16 |
Liron Elkouby |
An improved expression cassette for packaging and expression of variant Factor VIII for the treatment of hemostasis disorders
|
|
KR20170125941A
(ko)
|
2015-03-06 |
2017-11-15 |
체에스엘 베링 리컴비넌트 퍼실리티 아게 |
개선된 반감기를 갖는 변형된 폰 빌레브란트 인자
|
|
US9958572B2
(en)
|
2015-03-31 |
2018-05-01 |
Halliburton Energy Services, Inc. |
Synthetic test beds for fracturing optimization and methods of manufacture and use thereof
|
|
BR112017023785A2
(pt)
|
2015-05-22 |
2018-07-17 |
Csl Behring Recombinant Facility Ag |
polipeptídeos do fator de von willebrand truncados para tratar hemofilia
|
|
AU2016301303B2
(en)
|
2015-08-03 |
2021-10-07 |
Bioverativ Therapeutics Inc. |
Factor IX fusion proteins and methods of making and using same
|
|
ES2862412T3
(es)
|
2015-10-14 |
2021-10-07 |
Translate Bio Inc |
Modificación de enzimas relacionados con el ARN para producción mejorada
|
|
DK3400238T3
(da)
|
2016-01-07 |
2021-07-26 |
CSL Behring Lengnau AG |
Muteret von willebrand faktor
|
|
RU2018128582A
(ru)
|
2016-01-07 |
2020-02-11 |
Цсл Беринг Ленгнау Аг |
Мутированный укороченный фактор фон виллебранда
|
|
EP3476937A4
(fr)
|
2016-06-24 |
2019-12-04 |
Mogam Institute for Biomedical Research |
Protéine chimère comprenant les facteurs fviii et vwf, et utilisation de celle-ci
|
|
SG11201903954WA
(en)
|
2016-11-11 |
2019-05-30 |
CSL Behring Lengnau AG |
Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
|
|
CN110520149A
(zh)
|
2016-12-02 |
2019-11-29 |
比奥维拉迪维治疗股份有限公司 |
诱导对凝血因子的免疫耐受性的方法
|
|
WO2018102743A1
(fr)
|
2016-12-02 |
2018-06-07 |
Bioverativ Therapeutics Inc. |
Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
|
|
JP7763589B2
(ja)
|
2018-05-18 |
2025-11-04 |
バイオベラティブ セラピューティクス インコーポレイテッド |
血友病ａを処置する方法
|
|
JP7050015B2
(ja)
|
2019-01-17 |
2022-04-07 |
古河電池株式会社 |
鉛蓄電池
|
|
WO2021257899A1
(fr)
|
2020-06-19 |
2021-12-23 |
Bioverativ Therapeutics Inc. |
Procédés de traitement de l'hémophilie a et outils pharmacocinétiques de population pour déterminer des traitements et leurs utilisations
|
|
WO2022129303A1
(fr)
|
2020-12-18 |
2022-06-23 |
UCB Biopharma SRL |
Dérivés de dihydroisoquinolinyle
|